CDH1 Gene clinical trials
9 active trials name this biomarker in their eligibility criteria. Describe your situation to see which ones you may be eligible for.
- Avutometinib and Defactinib in Diffuse Gastric Cancer
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
- A Multi-Modality Surveillance Program for Women at High Risk for Breast Cancer
- CDH1-associated Blepharocheilodontic Syndrome Registry
- Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
- Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer
- Genetic & Pathological Studies of BRCA1/BRCA2: Associated Tumors & Blood Samples
- Environmental Exposure Assessment in High-Risk and Early-Onset Breast Cancer Care
Guides for people searching for a trial
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that name “CDH1 Gene” in their eligibility criteria, at any level. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.